Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine
Pharmaceutical Technology
OCTOBER 28, 2022
billion and $812 million in 2028. Competition in an increasingly heated market. Vaxcyte’s recent clinical success brings further competition into a sector, which is becoming increasingly heated. The post Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine appeared first on Pharmaceutical Technology.
Let's personalize your content